171 results
Search Results
2. Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
3. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO
4. Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
5. SLC35A2 expression is associated with HER2 expression in breast cancer
6. The expression of O-linked glycosyltransferase GALNT7 in breast cancer is dependent on estrogen-, progesterone-, and HER2-receptor status, with prognostic implications
7. Updates in the Pathology and Therapy of BRCA Germline–Associated Breast Cancer with a Focus on HER2 Amplification
8. The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer
9. Evaluation of homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide on HER2-over expressed breast cancer cells
10. Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer
11. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization
12. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer
13. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment
14. Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2 + Breast Cancer
15. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009–2016: a cross-sectional study
16. Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions
17. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
18. Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
19. The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review
20. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target
21. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
22. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval
23. Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levels
24. HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study
25. Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer
26. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
27. Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer
28. Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer
29. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
30. Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Cardiotoxicity in Patients with Breast Cancer
31. A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women
32. HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
33. Paget’s disease of the nipple in a Her2-positive breast cancer xenograft model
34. Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity
35. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
36. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
37. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
38. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)
39. Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases
40. Loss of HER2 after HER2-targeted treatment
41. Application of the D492 Cell Lines to Explore Breast Morphogenesis, EMT and Cancer Progression in 3D Culture
42. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
43. Molecular subtypes of screen-detected breast cancer
44. The Evolving Landscape of HER2-Directed Breast Cancer Therapy
45. Applying the New Guidelines of HER2 Testing in Breast Cancer
46. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition
47. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors
48. Current Treatment Options for Breast Cancer Brain Metastases
49. Search of MicroRNAs Regulating the Receptor Status of Breast Cancer In Silico and Experimental Confirmation of Their Expression in Tumors
50. Multifractal-based nuclei segmentation in fish images
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.